S. 161 would create a new article in Title 44 of the South Carolina Code focused on non-opioid treatments for pain management. The bill directs the Department of Health and Human Services to adopt or amend a state preferred drug list so that FDA-approved non-opioid pain medications are not placed at a disadvantage relative to opioid or narcotic pain drugs. It also bars managed care organizations and other health insurance issuers from denying coverage of a prescribed non-opioid pain medication in favor of an opioid alternative, and requires appropriate reimbursement for providers who furnish non-opioid treatment under the medical assistance program.
The bill also requires the Department of Public Health to create and post an educational pamphlet about non-opioid pain alternatives, including both drug and non-drug therapies, and to work with the South Carolina Opioid Recovery Fund to explore use of opioid abatement funding for related education and services. Before prescribing a Schedule II opioid for pain, healthcare practitioners would have to inform patients about non-opioid alternatives, discuss risks and benefits, provide the pamphlet, and document the alternatives considered, except in emergency care and before anesthesia.
Impact
If enacted, the bill would add Article 20 to Chapter 53, Title 44, creating new statutory requirements for Medicaid administration, managed care coverage decisions, public health education, and prescribing practices for opioid pain treatment. It would constrain how the Department of Health and Human Services structures the state preferred drug list and utilization controls, and it would impose patient-notification and documentation duties on prescribers of Schedule II opioids. The bill also sets a deadline of September 30, 2025, for the public health pamphlet to be posted online.
Sentiment
The available record suggests generally favorable sentiment toward the bill, with the Senate Medical Affairs Committee recommending that it “do pass” after amendment. The committee’s changes appear aimed at clarifying the bill’s language rather than altering its core policy direction, indicating support for the underlying goal of promoting non-opioid pain management and patient education. No floor votes or opposing testimony are included in the provided materials.
Contention
The main points of contention appear to be implementation details rather than the bill’s overall objective. The committee amended the bill to delete two sections and revise the patient-education requirement so providers must offer the pamphlet and document non-opioid alternatives considered, suggesting concern about precision, administrative burden, or duplicative language. Potentially sensitive issues include limits on agency discretion in preferred drug list decisions, coverage mandates for insurers and managed care organizations, and the extent of prescriber obligations before opioid prescribing.